NeOnc Technologies Holdings heads into its May 22 earnings report with one of the clearest insider-conviction signals of the quarter.
Chairman and CEO Amir Heshmatpour has purchased shares on seven separate occasions since early April, accumulating 60,000 shares at prices ranging from $4.16 to $6.32. The CFO and Chief Level Officer have also made open-market purchases during the same window. In total, insiders have net-bought 81,000 shares worth roughly $425,000 over the past 90 days — a persistent, repeated signal from the executive most familiar with what Thursday's numbers will show.
The buying is particularly notable given that the stock has spent much of that period under pressure. Shares closed at $5.50 on May 15, up about 2% over the past month but still trading far below the price targets recently attached by two initiating analysts. Maxim Group kicked off coverage yesterday with a Buy and a $20 price target; BTIG initiated in late April at Buy with a $15 target. Both are fresh, and together they imply more than 170% to 270% upside from current levels — a gap that reflects the speculative, pre-revenue nature of the clinical-stage oncology name rather than near-term price anchoring. The consensus sits at Buy with a mean target of $17.50, though the stock's $5.50 close means the Street is essentially pricing in a binary clinical outcome.
The short-selling picture offers little pressure in either direction. Short interest is modest at 1.5% of free float, down nearly 18% over the past week after a mid-April spike. Availability remains in normal territory at around 157% — well above the 52-week trough of 18.5% — meaning the borrow market is not particularly stressed. Cost to borrow did jump 34% in the past week to 4.5%, but that remains low in absolute terms and does not signal any meaningful squeeze dynamic. Bears are not pressing hard here.
What makes Thursday's print genuinely difficult to read is the stock's track record around earnings. Each of the three prior reported events produced a negative first-day move: -13%, -4.5%, and -10.5% respectively. The five-day windows were similarly punishing in two of three cases. That pattern sits in direct tension with the insider-buying cluster and the analyst enthusiasm — making May 22 a test of whether management's repeated open-market conviction reflects a fundamental turning point, or whether the market's post-earnings habit of selling the news reasserts itself once more.
See the live data behind this article on ORTEX.
Open NTHI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
